Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan S Zager

Showing results (71-80 of 321) with videos related to

Pageof 33
Sort By:
Expert Opinion on Drug Safety|August 8, 2023
A safety review of recently approved and late-stage trial treatments for metastatic melanoma: systemic and regional therapiesMatthew C Perez, Danielle K Depalo, Jonathan S Zager
Annals of Surgical Oncology|August 13, 2011
What is the significance of the in transit or interval sentinel node in melanoma?Jonathan S Zager, Christopher A Puleo, Vernon K Sondak
Cancer Control : Journal of the Moffitt Cancer Center|July 4, 2008
Therapy for unresectable recurrent and in-transit extremity melanomaMark I Gimbel, Keith A Delman, Jonathan S Zager
Expert Review of Anticancer Therapy|April 12, 2022
An update on local and systemic therapies for nonmelanoma skin cancerKelly M Elleson, Danielle K DePalo, Jonathan S Zager
Oncology (Williston Park, N.Y.)|October 19, 2016
Point: Surgical Management of Lymph Node Basin in Sentinel Lymph Node-Positive MelanomaAmod A Sarnaik, Jonathan S Zager, Vernon K Sondak
Annals of Surgical Oncology|September 1, 2019
The Landmark Series: Regional Therapy of Recurrent Cutaneous MelanomaGeorgia M Beasley, Jonathan S Zager, John F Thompson
Cancers|July 13, 2024
Clinical Characteristics and Special Considerations in the Management of Rare Melanoma SubtypesAdrienne B Shannon, Jonathan S Zager, Matthew C Perez
Current Problems in Cancer|August 16, 2015
Current approaches to cutaneous sarcomas: Dermatofibrosarcoma protuberans and cutaneous leiomyosarcomaEvan S Glazer, Carlos Prieto-Granada, Jonathan S Zager
Expert Opinion on Drug Safety|February 5, 2015
BRAF and MEK inhibition in melanomaLesly A Dossett, Ragini R Kudchadkar, Jonathan S Zager
Clinical & Experimental Metastasis|February 28, 2024
Editorial: Cancer metastasis through the lymphovascular system: molecular mechanisms of cancer metastasisStanley P Leong, S David Nathanson, Jonathan S Zager
Pageof 33

Showing results (71-80 of 321) with videos related to

Sort By:
Pageof 33
Expert Opinion on Drug Safety|August 8, 2023
A safety review of recently approved and late-stage trial treatments for metastatic melanoma: systemic and regional therapiesMatthew C Perez, Danielle K Depalo, Jonathan S Zager
Annals of Surgical Oncology|August 13, 2011
What is the significance of the in transit or interval sentinel node in melanoma?Jonathan S Zager, Christopher A Puleo, Vernon K Sondak
Cancer Control : Journal of the Moffitt Cancer Center|July 4, 2008
Therapy for unresectable recurrent and in-transit extremity melanomaMark I Gimbel, Keith A Delman, Jonathan S Zager
Expert Review of Anticancer Therapy|April 12, 2022
An update on local and systemic therapies for nonmelanoma skin cancerKelly M Elleson, Danielle K DePalo, Jonathan S Zager
Oncology (Williston Park, N.Y.)|October 19, 2016
Point: Surgical Management of Lymph Node Basin in Sentinel Lymph Node-Positive MelanomaAmod A Sarnaik, Jonathan S Zager, Vernon K Sondak
Annals of Surgical Oncology|September 1, 2019
The Landmark Series: Regional Therapy of Recurrent Cutaneous MelanomaGeorgia M Beasley, Jonathan S Zager, John F Thompson
Cancers|July 13, 2024
Clinical Characteristics and Special Considerations in the Management of Rare Melanoma SubtypesAdrienne B Shannon, Jonathan S Zager, Matthew C Perez
Current Problems in Cancer|August 16, 2015
Current approaches to cutaneous sarcomas: Dermatofibrosarcoma protuberans and cutaneous leiomyosarcomaEvan S Glazer, Carlos Prieto-Granada, Jonathan S Zager
Expert Opinion on Drug Safety|February 5, 2015
BRAF and MEK inhibition in melanomaLesly A Dossett, Ragini R Kudchadkar, Jonathan S Zager
Clinical & Experimental Metastasis|February 28, 2024
Editorial: Cancer metastasis through the lymphovascular system: molecular mechanisms of cancer metastasisStanley P Leong, S David Nathanson, Jonathan S Zager
Pageof 33